Navigation Links
Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
Date:7/2/2012

CRANBURY, N.J., July 2, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock, Series A warrants to purchase 31,988,151 shares of its common stock, and Series B warrants to purchase 35,488,380 shares of its common stock.  Funds under the management of QVT Financial LP have agreed to pay $0.50 for each share of common stock and $0.49 for each Series A warrant and each Series B warrant, resulting in gross proceeds to Palatin of $35,000,000, with net proceeds, after deducting estimated offering expenses, of approximately $34,500,000.

The private placement is expected to close on or about July 5, 2012, subject to customary closing conditions.

Palatin intends to use the proceeds from this offering for general corporate purposes and working capital, including its clinical trial program with bremelanotide for female sexual dysfunction, preclinical and clinical development of its melanocortin receptor-1 peptide program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.

Both Series A and Series B warrants are exercisable at an initial exercise price of $0.01 per share.  The Series A warrants are exercisable immediately upon issuance and expire on the tenth anniversary of the date of issuance.  The Series B warrants are also exercisable immediately upon issuance, but only if Palatin's stockholders increase the number of its authorized shares of common stock, and expire on the tenth anniversary of the date of the increase in the number of authorized shares.  Both the Series A warrants and the Series B warrants are subject to limitation on exercise if the holder and its affiliates would beneficially own more than 9.99% of the total number of Palatin's shares of common stock following such exercise.
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
9. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
10. Animal Biotechnology - Technologies, Markets and Companies
11. Gene Therapy - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... SHANGHAI , CAMBRIDGE, Mass. and ... -- WuXi NextCODE, which provides comprehensive capabilities for using the ... deCODE genetics on their publication of the largest studies of ... published today online in Nature Genetics ... date of sequence variation, authored by a team of deCODE ...
(Date:3/25/2015)... Fla. , March 25, 2015  Point-of-Care ... and management consulting firm, has launched the ePrescribing ... to simplify tracking of ePrescribing regulatory requirements in ... "The ePrescribing regulatory landscape continues to change rapidly, ... deliver what the industry, and ultimately patients, need," ...
(Date:3/25/2015)... Having added two International locations in Brisbane and ... Global proudly announced recently the organization’s expansion into Poland. ... in the United States, is one of the largest ... real estate. , Saltwood International is the ... advises occupiers of office space, ensuring that its corporate ...
(Date:3/25/2015)... LOUIS and the HAGUE, Netherlands ... of two-year results of LES Stimulation therapy for chronic ... the journal Surgery [ Surgery . ... efficacy of its minimally-invasive therapy. The ... average duration of 11 years and taking prescribed daily ...
Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2International Organization Expands its Global Reach to Warsaw, Poland 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3
... EST, WALTHAM, Mass., Jan. 31 Repligen Corporation,(Nasdaq: ... and Chief,Executive Officer, Walter C. Herlihy, Ph.D., will host ... at 11:00 a.m. EST, to report,third quarter fiscal year ... the Company., This call is being webcast by ...
... siRNA, to Identify 273 Human Proteins Needed for Reproduction of ... ... AIDS, WALTHAM, Mass., Jan. 31 Thermo Fisher,Scientific Inc., the ... has enabled a groundbreaking study,at Harvard Medical School in Boston, which ...
... 8:30 a.m. EST at ... http://www.isispharm.com , ... ) announced today that Abbott is,investing up to $40 million in ... further develop the Ibis T5000(TM),Biosensor System, which offers a unique solution ...
Cached Biology Technology:Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results 2Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results 3Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 2Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 3Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 4Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs 5Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 3Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 4
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
(Date:3/12/2015)... 2015 IriTech, a leading iris based identity ... Texas Instruments Design Network, announced today that the Chief ... IriShield USB MK2120U device during a launching event of ... The iris scanner is manufactured by ... India through its Indian partner, ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... League Baseball pitchers indicates that the height of the pitchers ... lead to potential injuries because of stress on the shoulder ... William Raasch, M.D., associate professor of orthopaedic surgery at the ... head team physician for the Milwaukee Brewers. Major League Baseball ...
... Walker is taking on one of the biggest killers in ... battle to save lives, especially the lives of children., With ... Walker will lead a research team studying how insecticide-treated bed ... causes the deadly disease, as well as the mosquito that ...
... many researchers have believed women choose partners based ... a new study from The University of Texas ... by their own attractiveness. David Buss, psychology ... in Attractive Women Want it All: Good Genes, ...
Cached Biology News:Study finds pitching mound height affects throwing motion, injury risk 2Netting mosquitoes to prevent malaria 2Do attractive women want it all? 2
Special grade: for electrophoresis...
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
This device is designed to run four simultaneous separations with the following StemSep ; column sizes: 0.3in., 0.5in., and 0.6in.. Depending on the column size, a range of 2x10 7 - 1.5 x 10 9 cell...
Contact us for more information...
Biology Products: